Joshua Kennedy
Concepts (237)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 19 | 2023 | 293 | 5.240 |
Why?
| Picornaviridae Infections | 10 | 2022 | 22 | 3.950 |
Why?
| Rhinovirus | 13 | 2022 | 26 | 3.640 |
Why?
| Rhinitis | 5 | 2018 | 33 | 2.610 |
Why?
| Sinusitis | 5 | 2018 | 57 | 2.510 |
Why?
| Desensitization, Immunologic | 5 | 2018 | 103 | 2.160 |
Why?
| Virus Diseases | 3 | 2023 | 43 | 1.930 |
Why?
| Hypersensitivity | 6 | 2022 | 82 | 1.770 |
Why?
| Drug Hypersensitivity | 3 | 2018 | 41 | 1.320 |
Why?
| Lung | 3 | 2023 | 512 | 1.190 |
Why?
| Respiratory Hypersensitivity | 4 | 2020 | 18 | 1.170 |
Why?
| Disaccharides | 2 | 2015 | 12 | 1.020 |
Why?
| Immunoglobulin E | 8 | 2020 | 92 | 1.000 |
Why?
| Rhinitis, Allergic, Perennial | 2 | 2014 | 4 | 1.000 |
Why?
| Androstadienes | 2 | 2014 | 9 | 1.000 |
Why?
| Urticaria | 2 | 2015 | 24 | 0.990 |
Why?
| Rhinitis, Allergic, Seasonal | 2 | 2014 | 5 | 0.990 |
Why?
| Meat | 2 | 2015 | 59 | 0.990 |
Why?
| Respiratory Sounds | 5 | 2022 | 54 | 0.950 |
Why?
| Viruses | 1 | 2023 | 21 | 0.930 |
Why?
| Pharyngitis | 1 | 2022 | 16 | 0.900 |
Why?
| Carbachol | 3 | 2020 | 33 | 0.860 |
Why?
| Streptococcal Infections | 1 | 2022 | 58 | 0.850 |
Why?
| Allergens | 6 | 2019 | 139 | 0.720 |
Why?
| Eosinophils | 3 | 2017 | 36 | 0.720 |
Why?
| Humans | 42 | 2023 | 54132 | 0.710 |
Why?
| Th2 Cells | 2 | 2016 | 26 | 0.710 |
Why?
| Bronchoconstriction | 1 | 2019 | 10 | 0.690 |
Why?
| Anaphylaxis | 2 | 2018 | 71 | 0.680 |
Why?
| Aspirin | 2 | 2017 | 127 | 0.660 |
Why?
| Bronchodilator Agents | 2 | 2019 | 74 | 0.650 |
Why?
| Mesalamine | 1 | 2017 | 8 | 0.610 |
Why?
| Ketorolac | 1 | 2016 | 2 | 0.600 |
Why?
| Itraconazole | 1 | 2016 | 45 | 0.590 |
Why?
| Colitis, Ulcerative | 1 | 2017 | 52 | 0.590 |
Why?
| Food Hypersensitivity | 2 | 2019 | 93 | 0.580 |
Why?
| Staphylococcus | 2 | 2013 | 33 | 0.580 |
Why?
| Viral Load | 3 | 2022 | 85 | 0.580 |
Why?
| Immunologic Factors | 1 | 2016 | 130 | 0.540 |
Why?
| Acetaminophen | 1 | 2019 | 349 | 0.530 |
Why?
| Child | 12 | 2023 | 7312 | 0.500 |
Why?
| Allergy and Immunology | 1 | 2013 | 15 | 0.480 |
Why?
| Candidiasis | 1 | 2014 | 122 | 0.470 |
Why?
| Hypersensitivity, Delayed | 1 | 2013 | 21 | 0.470 |
Why?
| Lymphangitis | 1 | 2013 | 2 | 0.460 |
Why?
| Manikins | 1 | 2013 | 40 | 0.460 |
Why?
| Emergency Medicine | 1 | 2013 | 60 | 0.460 |
Why?
| Bronchi | 1 | 2012 | 51 | 0.440 |
Why?
| Eosinophilia | 1 | 2013 | 37 | 0.440 |
Why?
| Common Cold | 1 | 2012 | 6 | 0.440 |
Why?
| Pruritus | 1 | 2013 | 53 | 0.440 |
Why?
| Edema | 1 | 2013 | 74 | 0.430 |
Why?
| Enterovirus Infections | 2 | 2022 | 6 | 0.410 |
Why?
| Chronic Disease | 4 | 2016 | 611 | 0.410 |
Why?
| Animals | 11 | 2020 | 14435 | 0.370 |
Why?
| Pediatrics | 1 | 2013 | 324 | 0.360 |
Why?
| Staphylococcal Infections | 1 | 2013 | 300 | 0.360 |
Why?
| Male | 16 | 2021 | 27350 | 0.350 |
Why?
| Interferons | 2 | 2022 | 44 | 0.340 |
Why?
| Adolescent | 11 | 2022 | 6890 | 0.340 |
Why?
| Anti-Allergic Agents | 2 | 2020 | 13 | 0.340 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1133 | 0.330 |
Why?
| Anti-Bacterial Agents | 1 | 2013 | 816 | 0.310 |
Why?
| Female | 15 | 2021 | 28437 | 0.300 |
Why?
| Bacteria | 2 | 2023 | 255 | 0.300 |
Why?
| Disease Progression | 3 | 2020 | 915 | 0.270 |
Why?
| Adult | 10 | 2022 | 14196 | 0.270 |
Why?
| Young Adult | 5 | 2022 | 4320 | 0.260 |
Why?
| Immunity, Innate | 2 | 2022 | 113 | 0.250 |
Why?
| Interleukins | 2 | 2015 | 39 | 0.250 |
Why?
| Skin Tests | 2 | 2013 | 58 | 0.230 |
Why?
| Child, Preschool | 6 | 2022 | 4132 | 0.230 |
Why?
| Swine | 2 | 2015 | 430 | 0.230 |
Why?
| Streptococcus pyogenes | 1 | 2022 | 17 | 0.230 |
Why?
| Respiratory Tract Infections | 2 | 2020 | 84 | 0.210 |
Why?
| Middle Aged | 5 | 2019 | 13094 | 0.210 |
Why?
| Autoantibodies | 1 | 2021 | 128 | 0.200 |
Why?
| Enterovirus | 1 | 2020 | 9 | 0.190 |
Why?
| Respiratory System | 1 | 2020 | 28 | 0.180 |
Why?
| Muscle, Smooth | 1 | 2020 | 69 | 0.180 |
Why?
| Calcium Signaling | 1 | 2020 | 59 | 0.180 |
Why?
| Organ Culture Techniques | 1 | 2019 | 53 | 0.170 |
Why?
| Disease Susceptibility | 1 | 2019 | 95 | 0.170 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 198 | 0.170 |
Why?
| Nasal Polyps | 1 | 2018 | 9 | 0.170 |
Why?
| Acetazolamide | 1 | 2018 | 20 | 0.170 |
Why?
| Arkansas | 4 | 2022 | 2103 | 0.160 |
Why?
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.160 |
Why?
| Albuterol | 1 | 2019 | 58 | 0.160 |
Why?
| RNA, Viral | 2 | 2020 | 142 | 0.160 |
Why?
| Food Supply | 1 | 2019 | 95 | 0.160 |
Why?
| Treatment Outcome | 5 | 2018 | 5596 | 0.160 |
Why?
| Emergency Service, Hospital | 1 | 2022 | 536 | 0.160 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 143 | 0.160 |
Why?
| Parainfluenza Virus 3, Human | 1 | 2017 | 7 | 0.150 |
Why?
| Respirovirus Infections | 1 | 2017 | 8 | 0.150 |
Why?
| Anticonvulsants | 1 | 2018 | 129 | 0.150 |
Why?
| Eosinophilic Esophagitis | 1 | 2017 | 32 | 0.150 |
Why?
| Th1-Th2 Balance | 1 | 2016 | 2 | 0.150 |
Why?
| Leukotrienes | 1 | 2016 | 10 | 0.150 |
Why?
| Pandemics | 1 | 2022 | 575 | 0.150 |
Why?
| Prevalence | 2 | 2019 | 1023 | 0.150 |
Why?
| Immunization | 2 | 2017 | 95 | 0.150 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1678 | 0.150 |
Why?
| Esophagus | 1 | 2017 | 79 | 0.150 |
Why?
| Health Literacy | 1 | 2019 | 141 | 0.140 |
Why?
| Cytokines | 2 | 2022 | 678 | 0.140 |
Why?
| Cells, Cultured | 2 | 2020 | 1755 | 0.140 |
Why?
| Immunocompromised Host | 1 | 2017 | 130 | 0.140 |
Why?
| Lymphocyte Activation | 1 | 2016 | 197 | 0.140 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 142 | 0.140 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 575 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 206 | 0.130 |
Why?
| Intracellular Membranes | 1 | 1995 | 28 | 0.130 |
Why?
| Basophils | 1 | 2014 | 16 | 0.130 |
Why?
| Candidiasis, Chronic Mucocutaneous | 1 | 2014 | 2 | 0.130 |
Why?
| Interleukin-17 | 1 | 2015 | 38 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1478 | 0.130 |
Why?
| Thymoma | 1 | 2014 | 11 | 0.130 |
Why?
| Myoglobin | 1 | 1995 | 32 | 0.130 |
Why?
| Eosinophil Cationic Protein | 1 | 2014 | 1 | 0.120 |
Why?
| Nasal Lavage Fluid | 1 | 2014 | 7 | 0.120 |
Why?
| Decision Making, Computer-Assisted | 1 | 2014 | 5 | 0.120 |
Why?
| Leukocyte Count | 1 | 2014 | 77 | 0.120 |
Why?
| Candida | 1 | 2014 | 67 | 0.120 |
Why?
| Administration, Intranasal | 1 | 2014 | 29 | 0.120 |
Why?
| Superantigens | 1 | 2013 | 1 | 0.120 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 75 | 0.120 |
Why?
| Markov Chains | 1 | 2014 | 34 | 0.120 |
Why?
| Nasal Mucosa | 1 | 2013 | 22 | 0.120 |
Why?
| Emergency Treatment | 1 | 2013 | 32 | 0.120 |
Why?
| Cell Differentiation | 1 | 2016 | 717 | 0.120 |
Why?
| Virginia | 1 | 2013 | 14 | 0.120 |
Why?
| Preoperative Period | 1 | 2013 | 59 | 0.120 |
Why?
| Decision Support Techniques | 1 | 2014 | 73 | 0.120 |
Why?
| Angioedema | 1 | 2013 | 9 | 0.120 |
Why?
| Cats | 1 | 2013 | 52 | 0.120 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2013 | 30 | 0.120 |
Why?
| Case-Control Studies | 2 | 2014 | 1242 | 0.110 |
Why?
| Paranasal Sinuses | 1 | 2013 | 22 | 0.110 |
Why?
| Oxidative Stress | 1 | 2019 | 953 | 0.110 |
Why?
| Cough | 1 | 2013 | 54 | 0.110 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 2021 | 0.110 |
Why?
| Affect | 1 | 2013 | 102 | 0.110 |
Why?
| Dogs | 1 | 2013 | 219 | 0.110 |
Why?
| Postoperative Period | 1 | 2013 | 191 | 0.110 |
Why?
| Sex Distribution | 1 | 2013 | 158 | 0.110 |
Why?
| Acute Disease | 1 | 2014 | 405 | 0.110 |
Why?
| Age Distribution | 1 | 2013 | 199 | 0.110 |
Why?
| Statistics, Nonparametric | 1 | 2013 | 233 | 0.110 |
Why?
| Cattle | 1 | 2013 | 224 | 0.110 |
Why?
| Pyroglyphidae | 1 | 2012 | 1 | 0.110 |
Why?
| Cost-Benefit Analysis | 1 | 2014 | 291 | 0.110 |
Why?
| Equipment Design | 1 | 2013 | 319 | 0.110 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 50 | 0.110 |
Why?
| Age Factors | 2 | 2014 | 1198 | 0.110 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 533 | 0.110 |
Why?
| Odds Ratio | 1 | 2014 | 603 | 0.110 |
Why?
| Myocardium | 1 | 1995 | 445 | 0.110 |
Why?
| Oxygen | 1 | 1995 | 358 | 0.110 |
Why?
| Antibodies, Viral | 2 | 2022 | 125 | 0.100 |
Why?
| Biofilms | 1 | 2013 | 200 | 0.100 |
Why?
| Patient Care Team | 1 | 2013 | 275 | 0.100 |
Why?
| Chemokine CXCL10 | 2 | 2022 | 20 | 0.100 |
Why?
| Virulence | 1 | 2012 | 194 | 0.100 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 239 | 0.100 |
Why?
| Prospective Studies | 2 | 2017 | 2607 | 0.100 |
Why?
| Logistic Models | 1 | 2014 | 991 | 0.100 |
Why?
| Clinical Competence | 1 | 2013 | 447 | 0.090 |
Why?
| Incidence | 1 | 2013 | 1084 | 0.090 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1210 | 0.080 |
Why?
| Cohort Studies | 1 | 2013 | 1549 | 0.080 |
Why?
| Hospitalization | 1 | 2013 | 704 | 0.080 |
Why?
| Time Factors | 2 | 2013 | 3223 | 0.080 |
Why?
| Genome, Viral | 2 | 2020 | 100 | 0.080 |
Why?
| Risk Assessment | 1 | 2013 | 1363 | 0.080 |
Why?
| Prognosis | 1 | 2013 | 2116 | 0.080 |
Why?
| United States | 1 | 2016 | 5172 | 0.070 |
Why?
| Respiratory Function Tests | 2 | 2020 | 98 | 0.070 |
Why?
| Interleukin-15 | 1 | 2022 | 19 | 0.050 |
Why?
| Serologic Tests | 1 | 2022 | 28 | 0.050 |
Why?
| Epidermal Growth Factor | 1 | 2022 | 38 | 0.050 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 68 | 0.050 |
Why?
| Multiple Myeloma | 1 | 2017 | 3024 | 0.050 |
Why?
| Interleukin-8 | 1 | 2022 | 97 | 0.050 |
Why?
| Infant | 2 | 2022 | 3797 | 0.050 |
Why?
| Cluster Analysis | 1 | 2022 | 250 | 0.050 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2021 | 24 | 0.050 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 60 | 0.050 |
Why?
| Renin-Angiotensin System | 1 | 2021 | 64 | 0.050 |
Why?
| Interleukin-6 | 1 | 2022 | 315 | 0.050 |
Why?
| Myosin Light Chains | 1 | 2020 | 5 | 0.050 |
Why?
| Placebo Effect | 1 | 2020 | 19 | 0.050 |
Why?
| Angiotensin II | 1 | 2021 | 166 | 0.050 |
Why?
| Histamine | 1 | 2020 | 28 | 0.050 |
Why?
| Primary Prevention | 1 | 2020 | 47 | 0.040 |
Why?
| Myocytes, Smooth Muscle | 1 | 2020 | 92 | 0.040 |
Why?
| Muscle Contraction | 1 | 2020 | 109 | 0.040 |
Why?
| Tertiary Healthcare | 1 | 2019 | 18 | 0.040 |
Why?
| Inflammation Mediators | 1 | 2020 | 128 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2020 | 178 | 0.040 |
Why?
| Hypersensitivity, Immediate | 1 | 2018 | 13 | 0.040 |
Why?
| Coculture Techniques | 1 | 2018 | 158 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 609 | 0.040 |
Why?
| Immune Tolerance | 1 | 2018 | 104 | 0.040 |
Why?
| Air Pollutants | 1 | 2018 | 70 | 0.040 |
Why?
| Double-Blind Method | 1 | 2020 | 747 | 0.040 |
Why?
| Particulate Matter | 1 | 2017 | 55 | 0.040 |
Why?
| Seasons | 1 | 2017 | 98 | 0.040 |
Why?
| Proton Pump Inhibitors | 1 | 2017 | 84 | 0.040 |
Why?
| Cross Infection | 1 | 2017 | 106 | 0.040 |
Why?
| Environmental Exposure | 1 | 2017 | 206 | 0.030 |
Why?
| Partial Pressure | 1 | 1995 | 17 | 0.030 |
Why?
| Phosphorus | 1 | 1995 | 30 | 0.030 |
Why?
| Receptors, Cytokine | 1 | 2014 | 13 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2017 | 743 | 0.030 |
Why?
| Protons | 1 | 1995 | 81 | 0.030 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 1995 | 252 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 2014 | 100 | 0.030 |
Why?
| Adenosine Triphosphate | 1 | 1995 | 253 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 153 | 0.030 |
Why?
| Exhalation | 1 | 2012 | 19 | 0.030 |
Why?
| Quality of Life | 1 | 2019 | 914 | 0.030 |
Why?
| Epitopes | 1 | 2012 | 88 | 0.030 |
Why?
| Risk | 1 | 2012 | 343 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 1995 | 1676 | 0.020 |
Why?
| Risk Factors | 1 | 2019 | 3936 | 0.020 |
Why?
| Nitric Oxide | 1 | 2012 | 298 | 0.020 |
Why?
| Spirometry | 1 | 2008 | 30 | 0.020 |
Why?
| Respiratory Therapy | 1 | 2008 | 38 | 0.020 |
Why?
| Rats | 1 | 1995 | 3435 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2008 | 96 | 0.020 |
Why?
| Administration, Oral | 1 | 2008 | 459 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 491 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2008 | 1084 | 0.020 |
Why?
| Retrospective Studies | 1 | 2017 | 6387 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2008 | 2384 | 0.010 |
Why?
|
|
Kennedy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|